Literature DB >> 24362504

[Use of cetuximab with definitive chemoradiotherapy for esophageal cancer results in decreased overall survival].

N H Nicolay1, K Herfarth.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24362504     DOI： 10.1007/s00066-013-0523-y

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  10 in total

1.  Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial.

Authors:  Alicia F C Okines; Sue E Ashley; David Cunningham; Jacqueline Oates; Andrea Turner; Janine Webb; Claire Saffery; Yu Jo Chua; Ian Chau
Journal:  J Clin Oncol       Date:  2010-08-02       Impact factor: 44.544

2.  Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.

Authors:  Kim L Wang; Tsung-Teh Wu; In Seon Choi; Huamin Wang; Erika Resetkova; Erika Reseetkova; Arlene M Correa; Wayne L Hofstetter; Stephen G Swisher; Jaffer A Ajani; Asif Rashid; Constance T Albarracin
Journal:  Cancer       Date:  2007-02-15       Impact factor: 6.860

3.  Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06).

Authors:  Thomas Ruhstaller; Miklos Pless; Daniel Dietrich; Helmut Kranzbuehler; Roger von Moos; Peter Moosmann; Michael Montemurro; Paul M Schneider; Daniel Rauch; Oliver Gautschi; Walter Mingrone; Lucas Widmer; Roman Inauen; Peter Brauchli; Viviane Hess
Journal:  J Clin Oncol       Date:  2011-01-04       Impact factor: 44.544

4.  Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity.

Authors:  Howard Safran; Mohan Suntharalingam; Thomas Dipetrillo; Thomas Ng; L Austin Doyle; Mark Krasna; Angela Plette; Devon Evans; Harold Wanebo; Paul Akerman; Jeremy Spector; Nancy Kennedy; Teresa Kennedy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-05       Impact factor: 7.038

5.  Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamous cell carcinoma.

Authors:  Yongshun Chen; Xiaoyuan Wu; Shanshan Bu; Chunyu He; Wen Wang; Jinsong Liu; Wei Guo; Bo Tan; Yanxia Wang; Jianhua Wang
Journal:  Cancer Sci       Date:  2012-09-14       Impact factor: 6.716

Review 6.  Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results.

Authors:  Michael Baumann; Mechthild Krause
Journal:  Radiother Oncol       Date:  2004-09       Impact factor: 6.280

7.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

Authors:  James A Bonner; Paul M Harari; Jordi Giralt; Nozar Azarnia; Dong M Shin; Roger B Cohen; Christopher U Jones; Ranjan Sur; David Raben; Jacek Jassem; Roger Ove; Merrill S Kies; Jose Baselga; Hagop Youssoufian; Nadia Amellal; Eric K Rowinsky; K Kian Ang
Journal:  N Engl J Med       Date:  2006-02-09       Impact factor: 91.245

8.  SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus.

Authors:  Christopher N Hurt; Lisette S Nixon; Gareth O Griffiths; Ruby Al-Mokhtar; Simon Gollins; John N Staffurth; Ceri J Phillips; Jane M Blazeby; Tom D Crosby
Journal:  BMC Cancer       Date:  2011-10-28       Impact factor: 4.430

9.  Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial.

Authors:  Thomas Crosby; Christopher N Hurt; Stephen Falk; Simon Gollins; Somnath Mukherjee; John Staffurth; Ruby Ray; Nadim Bashir; John A Bridgewater; J Ian Geh; David Cunningham; Jane Blazeby; Rajarshi Roy; Tim Maughan; Gareth Griffiths
Journal:  Lancet Oncol       Date:  2013-04-25       Impact factor: 41.316

10.  Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials.

Authors:  A F C Okines; D Gonzalez de Castro; D Cunningham; I Chau; R E Langley; L C Thompson; S P Stenning; C Saffery; Y Barbachano; F Coxon; G Middleton; D Ferry; T Crosby; S Madhusudan; J Wadsley; J Waters; M Hall; D Swinson; A Robinson; D Smith; J S Reis-Filho; T S Waddell; L Puckey; S Hulkki Wilson; Z Eltahir; M Band; A Wotherspoon
Journal:  Eur J Cancer       Date:  2013-03-05       Impact factor: 9.162
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.